Your session is about to expire
← Back to Search
CDX-527 for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer treatment on patients with selected solid tumors. The treatment will be given in escalating doses to determine a safe and effective dose. The trial will be conducted at multiple center and the treatment's effectiveness will be expanded.
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Bile Duct Cancer
- Peritoneal Carcinoma
- Head and Neck Cancers
- Colorectal Cancer
- Liver Tumors
- Kidney Cancer
- Stomach Cancer
- Esophageal Cancer
- Breast Cancer
- Solid Tumors
- Bladder Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there still opportunity for individuals to join this clinical experiment?
"According to clinicaltrials.gov, the recruitment period for this medical study has closed as of November 29th 2022; it was originally posted on August 4th 2020. Nevertheless, there are over 5400 other trials that currently need participants."
How many centers are actively overseeing this clinical trial?
"Presently, patients are being recruited from 5 distinct trial sites, which are located in Omaha, Durham and Portland as well as two other locales. To cut down on travel related expenses it is advisable to select the research centre closest to you if you decide to partake."
To what degree is CDX-527 hazardous to human health?
"Data collected on CDX-527's safety is limited, so we rated it a 1 out of 3. This treatment currently resides in Phase 1 trials and has yet to be thoroughly evaluated for efficacy and safety."
Share this study with friends
Copy Link
Messenger